Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PMN Stock Forecast 2025-2026
$0.50
Current Price
$16.22M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PMN Price Targets
+1,516.5%
To High Target of $8.08
+1,112.5%
To Median Target of $6.06
+506.2%
To Low Target of $3.03
PMN Price Momentum
-2.0%
1 Week Change
-15.3%
1 Month Change
-70.2%
1 Year Change
-47.4%
Year-to-Date Change
-78.9%
From 52W High of $2.37
+6.4%
From 52W Low of $0.47
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching ProMIS (PMN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PMN and similar high-potential opportunities.
Latest PMN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PMN has a bullish consensus with a median price target of $6.06 (ranging from $3.03 to $8.08). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $0.50, the median forecast implies a 1,112.5% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PMN Analyst Ratings
3
Buy
0
Hold
0
Sell
PMN Price Target Range
Low
$3.03
Average
$6.06
High
$8.08
Current: $0.50
Latest PMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PMN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | Maxim Group | Jason McCarthy | Buy | Initiates | $3.00 |
| Apr 1, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $6.00 |
| Feb 26, 2025 | Guggenheim | Eddie Hickman | Buy | Reiterates | $0.00 |
| Oct 3, 2023 | BTIG | Thomas Shrader | Buy | Initiates | $8.00 |
ProMIS Neurosciences Inc. (PMN) Competitors
The following stocks are similar to ProMIS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProMIS Neurosciences Inc. (PMN) Financial Data
ProMIS Neurosciences Inc. has a market capitalization of $16.22M with a P/E ratio of 5.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -19.6%.
Valuation Metrics
Market Cap
$16.22M
Enterprise Value
$8.76M
P/E Ratio
5.5x
PEG Ratio
-0.8x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+51.4%
Current Ratio
3.4x
Debt/Equity
0.0x
ROE
-19.6%
ROA
-124.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ProMIS Neurosciences Inc. (PMN) Business Model
About ProMIS Neurosciences Inc.
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
ProMIS Neurosciences operates by utilizing its proprietary technology platform to identify misfolded proteins linked to neurodegenerative diseases. The company primarily generates revenue through the development of precision medicines aimed at addressing unmet medical needs in conditions such as Alzheimer's and ALS, often collaborating with academic institutions and strategic partners to enhance its research and accelerate therapeutic development.
Additional Information
Headquartered in Toronto, Canada, ProMIS is positioned as a significant player in the biotech sector, contributing to advancements in targeted therapies within the pharmaceutical and healthcare industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
7
CEO
Mr. Neil K. Warma M.B.A.
Country
Canada
IPO Year
2022
Website
www.promisneurosciences.comProMIS Neurosciences Inc. (PMN) Latest News & Analysis
Latest News
Quick Summary
ProMIS Neurosciences completed the first cohort in the PRECISE-AD trial for PMN310 in Alzheimer's. Six-month interim results are expected in 1H 2026, with topline results by year-end 2026.
Why It Matters
Progress in the PRECISE-AD trial signals potential advancements in Alzheimer's treatments, influencing ProMIS Neurosciences' valuation and investor sentiment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The PRECISE-AD trial has begun rapid enrollment and dosing of its first patients, highlighting the demand for improved Alzheimer's disease treatments.
Why It Matters
The rapid enrollment in the PRECISE-AD trial signals strong investment potential in Alzheimer's treatments, highlighting a growing market for innovative therapies amid high demand.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences Inc. will present virtually at the 2025 AD/PD International Conference in Vienna from April 1-4, focusing on therapies for neurodegenerative diseases.
Why It Matters
ProMIS Neurosciences' participation in a major conference highlights its commitment to advancing treatments for neurodegenerative diseases, potentially influencing stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences Inc. will present preclinical data on its computationally-derived vaccines for neurodegenerative diseases at the AAN Annual Meeting from April 5-9, 2025.
Why It Matters
ProMIS Neurosciences' presentation of preclinical data on vaccines for neurodegenerative diseases could signal advancements in treatment, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProMIS Neurosciences (Nasdaq: PMN) CEO Neil Warma will speak at the 37th Annual Roth Conference on March 18, 2025, discussing their antibody therapeutics for neurodegenerative diseases.
Why It Matters
ProMIS Neurosciences' CEO's participation at a major conference signals potential positive developments in their drug pipeline, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease
2 months ago
Quick Summary
ProMIS Neurosciences has initiated patient dosing in its Phase 1b trial for Alzheimer's drug PMN310. Six-month interim results are expected in 1H 2026, with topline results in 2H 2026.
Why It Matters
ProMIS Neurosciences' progress in its Alzheimer's trial highlights potential breakthroughs in treatment, which could significantly impact stock value and market perception in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PMN Stock
What is ProMIS Neurosciences Inc.'s (PMN) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, ProMIS Neurosciences Inc. (PMN) has a median price target of $6.06. The highest price target is $8.08 and the lowest is $3.03.
Is PMN stock a good investment in 2025?
According to current analyst ratings, PMN has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PMN stock?
Wall Street analysts predict PMN stock could reach $6.06 in the next 12 months. This represents a 1,112.5% increase from the current price of $0.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProMIS Neurosciences Inc.'s business model?
ProMIS Neurosciences operates by utilizing its proprietary technology platform to identify misfolded proteins linked to neurodegenerative diseases. The company primarily generates revenue through the development of precision medicines aimed at addressing unmet medical needs in conditions such as Alzheimer's and ALS, often collaborating with academic institutions and strategic partners to enhance its research and accelerate therapeutic development.
What is the highest forecasted price for PMN ProMIS Neurosciences Inc.?
The highest price target for PMN is $8.08 from at , which represents a 1,516.5% increase from the current price of $0.50.
What is the lowest forecasted price for PMN ProMIS Neurosciences Inc.?
The lowest price target for PMN is $3.03 from at , which represents a 506.2% increase from the current price of $0.50.
What is the overall PMN consensus from analysts for ProMIS Neurosciences Inc.?
The overall analyst consensus for PMN is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.06.
How accurate are PMN stock price projections?
Stock price projections, including those for ProMIS Neurosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 4:12 AM UTC